Core Viewpoint - The announcement highlights the upcoming presentation of clinical data for two key drug candidates, CS2009 and CS5001, at the 2025 ESMO annual meeting, marking significant milestones for the company in the oncology sector [1] Group 1: Clinical Trials and Data - The company will present preliminary data from the ongoing Phase I dose-escalation study of CS2009, a tri-specific antibody targeting PD-1, VEGF, and CTLA-4, involving approximately 70 patients with advanced solid tumors [1] - The abstract for CS2009 includes data from 9 patients as of the submission deadline on May 8, 2025, fulfilling ESMO's submission requirements [1] - The clinical data for CS5001, an antibody-drug conjugate targeting ROR1, will also be summarized in the ongoing Phase Ib study design [1]
基石药业-B(02616.HK)：将公布PD-1/VEGF/CTLA-4三抗I期剂量递增临床数据和ROR1ADC最新研究设计